> ## Content Index > Fetch the complete content index at: https://brief.sharpertrades.com/llms.txt > Use this file to discover other available public pages before exploring further. # Pfizer’s Oncology Growth Drives Higher 2026 Outlook as COVID Sales Decline - URL: https://brief.sharpertrades.com/pfizers-oncology-growth-drives-higher-2026-outlook-as-covid-sales-decline/ - Published: 2026-11-03T17:16:22.000Z - Updated: 2026-11-03T17:16:22.000Z - Description: Pfizer raised its 2026 earnings and revenue forecasts after stronger-than-expected third-quarter results. Growth in oncology and newer medicines helped offset declining COVID-19 sales, while investors remained focused on the company's longer-term pipeline. - Author: Luca Moschini - Tags: Earnings, Business Trends, Sector ### New Medicines Support Pfizer’s Post-Pandemic Transition Pfizer (PFE) raised its full-year financial outlook on November 3 after reporting third-quarter revenue and adjusted earnings above Wall Street expectations. Growth in cancer treatments and recently launched medicines helped counter continued weakness in its COVID-19 business. Despite the improved guidance, the market reaction was muted, with shares showing only modest movement following the announcement. Investors remain focused on whether Pfizer can sustain growth outside its pandemic-era products and develop its next generation of treatments. --- ### Key Points - **Pfizer raises guidance:** The company increased its 2026 revenue outlook to $62 billion–$64 billion and adjusted earnings guidance to $2.95–$3.05 per share. - **New medicines drive growth:** Revenue from recently launched and acquired products increased 32%, led by strength in oncology and other established treatments. - **COVID declines remain a challenge:** Falling sales of Paxlovid and Comirnaty continued to weigh on overall revenue, keeping attention on Pfizer's pipeline and diversification strategy. --- ## Pfizer Raises Its 2026 Outlook After Stronger Earnings Pfizer reported third-quarter revenue of approximately $16.6 billion, exceeding Wall Street's estimate of $15.85 billion but remaining roughly unchanged from a year earlier. Adjusted earnings reached $0.87 per share, above the approximately $0.74 expected by analysts. Reported net income declined to $3.24 billion from $3.54 billion in the prior-year quarter. The results prompted management to raise its full-year forecasts. Pfizer now expects 2026 revenue between $62 billion and $64 billion, compared with its previous outlook of $60.5 billion to $62.5 billion. Adjusted earnings guidance increased to $2.95–$3.05 per share, up from the earlier range of $2.80–$3.00\. The improved outlook reflects stronger year-to-date performance and growing contributions from newer medicines. Chief Executive Albert Bourla highlighted the company's expanding portfolio and upcoming clinical developments as important components of Pfizer's longer-term strategy. The company also appointed Cecile Guegan as chief financial officer after she had served in the position on an interim basis since August. ## How Is Pfizer Offsetting Declining COVID-19 Revenue? Pfizer's latest earnings highlighted the ongoing transition away from the extraordinary demand for COVID-19 vaccines and treatments during the pandemic. Revenue from Paxlovid, its antiviral treatment, declined 63%, while sales of the Comirnaty vaccine fell 29%. The declines reflected lower COVID-19 infection rates and continued weakness in demand for pandemic-related products. Pfizer also experienced softer sales in its Prevnar pneumococcal vaccine franchise, where revenue declined 10% amid competition and lower immunization rates. However, growth elsewhere in the portfolio helped offset those pressures. Excluding COVID-19 products, revenue increased 7% on a currency-adjusted basis, and sales from recently launched and acquired medicines climbed 32%. Oncology was a particularly important contributor. Padcev, a treatment used in certain bladder cancers, recorded revenue growth of 55%, supported by market-share gains. Lorbrena, a treatment for a form of advanced lung cancer, grew 43% as adoption increased in the United States and China. Meanwhile, Eliquis, Pfizer's blood thinner developed with Bristol Myers Squibb (BMY), generated approximately $2.5 billion in quarterly revenue, representing 25% growth. The results demonstrate how Pfizer's broader pharmaceutical portfolio is increasingly supporting revenue as its COVID-19 business contracts. ## Weight-Loss Treatments and Oncology Shape Pfizer’s Next Growth Phase Beyond its current product portfolio, Pfizer is investing in new treatments intended to support growth over the coming years. One major focus is obesity medicine, where the company is seeking to establish a stronger presence after discontinuing development of its earlier oral weight-loss candidate, danuglipron. Pfizer is now advancing berobenatide, a treatment acquired through its approximately $10 billion purchase of Metsera in late 2025\. The company plans to introduce a weekly formulation in 2028, followed by a monthly injectable version, subject to the necessary development and regulatory milestones. Pfizer is also studying MET-233i, another treatment obtained through the acquisition, both independently and in combination with berobenatide. These programs would position Pfizer to compete in a market currently led by Eli Lilly (LLY) and Novo Nordisk (NVO). However, clinical results remain an important uncertainty. Jefferies analyst Akash Tewari has cautioned that expectations for upcoming early-stage trial results should remain measured. Oncology represents another important area of development. Pfizer's existing cancer portfolio is already delivering revenue growth, while its broader pipeline offers additional opportunities to introduce new treatments. The central challenge is translating clinical progress into successful commercial products capable of sustaining growth as older medicines face competition and declining demand. --- ## What It Means for Investors Pfizer's third-quarter results provide evidence that growth outside its COVID-19 portfolio is helping stabilize the company's financial performance. The raised guidance reflects stronger contributions from established medicines and recently launched treatments, particularly in oncology. However, the modest stock reaction suggests investors are looking beyond the immediate earnings improvement. The important questions concern the durability of growth in non-COVID products, the company's ability to manage declining revenue from older medicines, and the progress of its clinical pipeline. Pfizer's expansion into obesity treatments also introduces development and execution risks, particularly given the competitive landscape and the company's previous setback with danuglipron. For investors following PFE stock, upcoming clinical results and the continued performance of newer medicines will provide additional evidence of whether Pfizer's post-pandemic transition is gaining sustainable momentum. --- ## Conclusion Pfizer's stronger-than-expected third-quarter earnings and higher 2026 outlook mark progress in its effort to diversify beyond COVID-19 products. Growth in oncology, Eliquis, and recently launched medicines helped counter falling pandemic-related revenue, while the developing obesity portfolio represents another potential growth opportunity. The muted market response highlights continued uncertainty around future growth. The next phase of Pfizer's transformation will depend on sustaining commercial momentum and successfully advancing new treatments through development and regulatory review. --- ## FAQs ### Why did Pfizer raise its 2026 earnings outlook? Pfizer raised its outlook after stronger-than-expected third-quarter results and continued growth in recently launched and acquired medicines. The company now expects adjusted earnings of $2.95–$3.05 per share and revenue of $62 billion–$64 billion. ### How did Pfizer perform in the third quarter of 2026? Pfizer reported approximately $16.6 billion in revenue, exceeding Wall Street expectations. Adjusted earnings reached $0.87 per share, while reported net income declined to $3.24 billion. ### Which medicines are driving Pfizer's growth? Growth was supported by oncology treatments including Padcev and Lorbrena, along with stronger sales of Eliquis and other medicines. Revenue from recently launched and acquired products increased 32%. ### Why are Pfizer's COVID-19 sales declining? Pfizer reported lower demand for its COVID-19 products as infection rates declined. Paxlovid revenue fell 63%, while Comirnaty vaccine sales decreased 29%. ### What is Pfizer developing in the weight-loss market? Pfizer is developing berobenatide, acquired through its purchase of Metsera, with plans for weekly and monthly injectable formulations. The company is also evaluating MET-233i as a standalone treatment and in combination with berobenatide. *This article was created with AI assistance and reviewed by an editor. For details, please refer to our* [*Terms of Use*](https://sharpertrades.com/p/terms?ref=brief.sharpertrades.com)*.* --- ### Go Beyond the Market Brief with Market Edge Follow SharperTrades’ complete approach to trading and investing, combining active trade opportunities through Block Orders, long-term research through Stock Investor, and structured market education through the Swing Trading Masterclass.[*Try Market Edge for $19 your first month →*](https://sharpertrades.com/p/market-edge?coupon%5Fcode=MB19&ref=brief.sharpertrades.com) ### Explore Research with Stock Investor [*Stock Investor*](https://sharpertrades.com/p/stock-investor/?ref=brief.sharpertrades.com) is SharperTrades’ platform for long-term investing research and portfolio management. Members receive research reports, portfolio updates, conviction tracking, and in-depth analysis designed to support disciplined investment decisions. ### Explore Active Trading & Income Strategies [*Block Orders*](https://sharpertrades.com/p/block-orders?ref=brief.sharpertrades.com) tracks institutional activity and highlights active trade setups and price behavior across long and short opportunities. For options-focused traders, [*Essential Option Income*](https://sharpertrades.com/p/option-alert-trading-signal?coupon%5Fcode=MB1&ref=brief.sharpertrades.com) provides a structured approach to options income strategies, while [*Pro Option Trader*](https://sharpertrades.com/p/pro-option-alert-trading-signal?coupon%5Fcode=MB19&ref=brief.sharpertrades.com) offers a broader range of options strategies and trade opportunities. ### Think More Clearly with SteadyCapital [SteadyCapital](https://studio.com/luca/steadycapital?c=fVDR9OI2&ref=brief.sharpertrades.com) is SharperTrades’ decision-support system for long-term investors, built around the SteadyCapital Method™. Review investment ideas, challenge assumptions, evaluate valuation and risk, compare companies, and think through important buy, hold, add, trim, or sell decisions before you act. ### Risk Disclosure All content is provided for educational purposes only and does not constitute investment advice. Trading involves risk, and past performance is not indicative of future results. Please review our full [Risk Disclosure](https://sharpertrades.com/p/risk-disclaimer?ref=brief.sharpertrades.com) for additional information.